Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw

Key Points

• Rodman & Renshaw initiated coverage with a buy rating and a $20 price target, implying about a 64% upside from the prior close.
• Enanta beat quarterly estimates (EPS loss of $0.42 vs. $0.54 expected; revenue $18.62M vs. $16.14M) but remains unprofitable with a negative net margin (106.8%) and analysts forecast -4.65 EPS for the year; the stock trades near $12.17 with a ~$353M market cap.
• Consensus among analysts is a Moderate Buy (seven Buys, one Sell) with an average price target of $20.29, and institutional investors hold roughly 94.99% of the shares.

Research analysts at Rodman & Renshaw began coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) in a report issued on Thursday. The firm set a "buy" rating and a $20.00 price target on the biotechnology company's stock. Rodman & Renshaw's target price suggests a potential upside of 64.34% from the company's previous close.

A number of other equities analysts have also issued reports on ENTA. Weiss Ratings reissued a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enanta Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $20.29.

Enanta Pharmaceuticals Trading Up 0.7%

ENTA stock opened at $12.17 on Thursday. The company has a market capitalization of $353.17 million, a P/E ratio of -3.80 and a beta of 0.96. The business has a 50 day simple moving average of $13.45 and a 200-day simple moving average of $12.59. Enanta Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.12. The firm had revenue of $18.62 million during the quarter, compared to analysts' expectations of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. Research analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Meeder Asset Management Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $32,000. Seven Fleet Capital Management LP purchased a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth $36,000. Strs Ohio acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth $50,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 333.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company's stock worth $57,000 after buying an additional 2,758 shares in the last quarter. Finally, Quarry LP purchased a new position in Enanta Pharmaceuticals in the third quarter valued at about $81,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.